GlassScriptPhysician profile
Arkady B Kagan
NPI 1790839538
$3,898.20
in general payments reported to CMS, 2019-2025
24 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $406 · 2021: $424 · 2022: $616 · 2023: $556 · 2024: $445 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $709.49 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $704.04 | 2019-2025 | |
| Allergan, INC. | $433.06 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $428.73 | 2021-2025 | Xeomin |
| Bausch & Lomb Americas INC. | $411.31 | 2022-2023 | Miebo |
| Aerie Pharmaceuticals, INC. | $176.75 | 2019-2021 | |
| Beaver-Visitec International, INC. | $151.60 | 2021 | |
| Lumenis Be INC | $144.92 | 2023 | M22 |
| Kala Pharmaceuticals, INC. | $120.29 | 2019 | |
| Sight Sciences, INC. | $118.77 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $105.53 | 2019 | |
| Abbvie INC. | $68.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $56.15 | 2021 | |
| Eyevance Pharmaceuticals LLC | $39.45 | 2019-2022 | |
| Merz North America, INC. | $32.85 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $31.69 | 2019 | |
| Oyster Point Pharma, INC. | $28.74 | 2025 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $24.87 | 2024 | Iyuzeh |
| Ocular Therapeutix, INC. | $23.95 | 2022 | |
| Rxsight INC | $23.04 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Galderma Laboratories, L.P. | $20.56 | 2022 | |
| Harrow Eye, LLC | $15.69 | 2025 | Vevye |
| Dompe US, INC. | $15.00 | 2023 | Oxervate |
| Glaukos Corporation | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Kagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.